Reshape Lifesciences (Reshape Lifesciences) ROC (Joel Greenblatt) %

: -351.41% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Reshape Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -351.41%.

The historical rank and industry rank for Reshape Lifesciences's ROC (Joel Greenblatt) % or its related term are showing as below:

RSLS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -19065.02 Med: -5456.79 Max: -684.01
Current: -684.01

During the past 13 years, Reshape Lifesciences's highest ROC (Joel Greenblatt) % was -684.01%. The lowest was -19065.02%. And the median was -5456.79%.

RSLS's ROC (Joel Greenblatt) % is ranked worse than
87.51% of 849 companies
in the Medical Devices & Instruments industry
Industry Median: 0.48 vs RSLS: -684.01

Reshape Lifesciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 45.20% per year.

Reshape Lifesciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for Reshape Lifesciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROC (Joel Greenblatt) %

-17,815.99

-2,168.07

-4,520.62

-2,091.77

-886.41

Reshape Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROC (Joel Greenblatt) %																-1,912.11	-1,299.57	-962.26	-557.22	-351.41

Competitive Comparison

For the Medical Devices subindustry, Reshape Lifesciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reshape Lifesciences ROC (Joel Greenblatt) % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's ROC (Joel Greenblatt) % falls into.

Reshape Lifesciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %

EBIT

Average of (Net fixed Assets

Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.153	+	3.204	+	0.538)	-	(3.434	+	0.657	+	0.268)
=	1.536

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.659	+	3.741	+	0.39)	-	(2.806	+	0.639	+	0.221)
=	2.124

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Reshape Lifesciences for the quarter that ended in Dec. 2023 can be restated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.58	/	( ( (0.344 + max(1.536, 0))	+	(0.31 + max(2.124, 0)) )	/	2 )
=	-7.58	/	( ( 1.88	+	2.434 )	/	2 )
=	-7.58	/	2.157
=	-351.41 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Reshape Lifesciences (NAS:RSLS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.

Reshape Lifesciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.

Reshape Lifesciences (Reshape Lifesciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » ROC (Joel Greenblatt) %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Calle Amanecer, San Clemente, CA, USA, 92673

Website

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Executives

Thomas Stankovich	officer: Chief Financial Officer	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey	director, officer: President and CEO	2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy	director	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee	director	C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford	director	7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald	officer: Chief Retail Officer	C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt	officer: Vice President of Marketing	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr	10 percent owner	467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022